Antilymphocyte immunoglobulin (horse)
- Generic Name
- Antilymphocyte immunoglobulin (horse)
- Brand Names
- Atgam
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 475247QF1Z
- Background
Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The result is polyclonal IgG that is then p...
- Indication
For prevention of renal transplant rejection and for the treatment of aplastic anemia.
- Associated Conditions
- Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Kidney Transplant Rejection, Lung Transplant Rejection, Moderate Aplastic Anemia, Myelodysplastic Syndrome, Severe Aplastic Anemia (SAA)
- Associated Therapies
- -
A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia
- Conditions
- Interventions
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 51
- Registration Number
- NCT03025698
- Locations
- 🇺🇸
Aflac Cancerand Blood Disorders Ctr, Atlanta, Georgia, United States
🇺🇸Ann and Robert H Lurie Childrens Hospital of Chicago SC, Chicago, Illinois, United States
🇺🇸Cleveland Clinic Foundation Cleveland Clinic 5, Cleveland, Ohio, United States
hATG+CsA vs hATG+CsA+Eltrombopag for SAA
- First Posted Date
- 2014-03-31
- Last Posted Date
- 2020-12-22
- Target Recruit Count
- 202
- Registration Number
- NCT02099747
- Locations
- 🇨🇭
University Hospital Bern, Bern, Switzerland
🇳🇱UMCG, Groningen, Netherlands
🇨🇭University Hospital Zürich, Zürich, Switzerland
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 38
- Registration Number
- NCT01019876
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.